A promising event recently occurred that some day may bring help to us. On November 13, Insmed, the pharmaceutical company behind Arikayce, received a PRIME designation from the European Medicine Agency for their drug BRENSOCATIB. This drug is an oral med that stops the release of a protein that actuates neutrophils which release an enzyme that damages the lungs of people with bronchiectasis.

A PRIME designation supports continuing research to bring promising treatment to patients.

Jump to this post